News
Market and company headlines
TECHAll
Loading
10:00Yesterday1 Story
07:00-11:00Oct 92 Stories
1 Unpopular Stock That Should Get More Attention and 2 We Question
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
Bio-Techne opens GMP small molecule facility in Bristol, UK
The purpose-built site is fully operational and produces materials to support developers working on cell therapies globally.
04:00-09:00Oct 82 Stories
Bio-Techne Expands Global GMP Manufacturing Network with New Bristol Facility to Advance Scalable Cell Therapy Development
Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced the opening of a new manufacturing facility for Good Manufacturing Practice (GMP) grade small molecules in Bristol, United Kingdom, further expanding the company's global capabilities to support the rapidly growing cell therapy market. The investment reflects Bio-Techne's commitment to helping therapy developers address one of the industry's most pressing challenges:
Bio-Techne Opens New Bristol Facility
Investment strengthens Bio-Techne's global GMP manufacturing infrastructure for cell therapy applicationsNew Bristol facility expands GMP small molecule production capacity and complements recent investments in
07:00Oct 11 Story
09:00Sep 281 Story
07:00-00:00Sep 252 Stories
Bio-Techne (TECH) Shareholders Approve the Merck KGaA Takeover and Reject the Pay Package
Bio-Techne Corporation (NASDAQ:TECH) shareholders voted on September 23 to approve the company’s acquisition by Merck KGaA of Darmstadt, Germany. The German group is paying $73 a share in cash, valuing the business at about $11.3 billion including debt. They also voted down the executive compensation proposal attached to the deal, which is an unusual pairing. […]
Robert V Baumgartner Exercises Options, Realizes $754K
Robert V Baumgartner, Board Member at Bio-Techne (NASDAQ:TECH), reported a large exercise of company stock options on September 24, according to a new SEC filing. What Happened: In an insider options exercise disclosed
04:00Sep 241 Story
09:00Sep 232 Stories
3 Reasons to Sell TECH and 1 Stock to Buy Instead
Bio-Techne has had an impressive run over the past six months as its shares have beaten the S&P 500 by 21.5%. The stock now trades at $72.56, marking a 39.5% gain. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany
Bio-Techne Corporation (NASDAQ: TECH) ("Bio-Techne"), a global provider of life science tools, reagents and diagnostic products, announced that Bio-Techne shareholders voted to approve and adopt the definitive agreement under which Merck KGaA, Darmstadt, Germany proposes to acquire Bio-Techne (the "Merger Agreement") at a Special Meeting of Shareholders held today.
05:00Sep 231 Story
09:00Sep 221 Story
00:00Sep 151 Story
11:00Sep 111 Story
02:00-08:00Sep 12 Stories
Bio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate Goals
Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced significant progress toward its climate and sustainability objectives, including validation of its greenhouse gas reduction targets by the Science Based Targets initiative (SBTi) and substantial reductions in operational emissions during fiscal year 2026.
Bio-Techne Announces SBTi Validation Of 70% Scope 1 & 2 Emissions Reduction Target By FY2031 And Supplier Engagement Commitment, Reporting Significant Operational Emissions Cuts In FY2026
Fiscal 2026 highlights:Science Based Targets initiative validates Bio-Techne's Scope 1, 2 and 3 greenhouse gas reduction targetsMarket-based Scope 1 and 2 emissions reduced 49% year-over-yearMore than half of the
18:00Aug 311 Story
06:00Aug 261 Story
06:00Aug 241 Story
11:00Aug 211 Story
06:00Aug 181 Story
18:00Aug 171 Story
06:00-14:00Aug 132 Stories
Wells Fargo Downgrades Bio-Techne to Equal-Weight, Raises Price Target to $73
Wells Fargo analyst Brandon Couillard downgrades Bio-Techne (NASDAQ:TECH) from Overweight to Equal-Weight and raises the price target from $62 to $73.
Bio-Techne Corrects Dividend Announcement
Bio-Techne Corporation (NASDAQ: TECH) is issuing a correction to its dividend announcement released yesterday. The initial version incorrectly stated the shareholder of record date as August 17, 2026. The correct shareholder of record date is August 24, 2026. All other information contained in the dividend announcement remains unchanged.
07:00Aug 122 Stories
Techne (TECH) Q4 Earnings Meet Estimates
Techne (TECH) delivered earnings and revenue surprises of 0.00% and +1.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Bio-Techne (NASDAQ:TECH) Surprises With Q2 CY2026 Sales
Life sciences company Bio-Techne (NASDAQ:TECH) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 1.3% year on year to $321.2 million. Its non-GAAP profit of $0.52 per share was in line with analysts’ consensus estimates.
06:00Aug 122 Stories
Bio-Techne Releases Fourth Quarter Fiscal 2026 Results
Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ending June 30, 2026.
Bio-Techne Declares Dividend
Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2026. The quarterly dividend will be payable August 28, 2026, to all common shareholders of record on August 17, 2026. Future cash dividends will be considered by the Board of Directors on a quarterly basis.